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Summary We have established a novel ascites tumour model (MDA435/LCC6) from the oestrogen receptor-
negative, invasive and metastatic MDA-MB-435 human breast cancer cell line. MDA435/LCC6 cells grow as
both malignant ascites and solid tumours in vivo in nude mice and nude rats, with a tumour incidence of
approximately 100%. Untreated mice develop ascites following i.p. inoculation of 1 x 106 cells and have a
reproducible life span of approximately 30 days, with all animals dying within a 48 h period. The in vivo
response of MDA435/LCC6 ascites to several cytotoxic drugs, including doxorubicin, etoposide (VP-16),
BCNU and mitomycin C, closely reflects the activity of these single agents in previously untreated breast
cancer patients. MDA435/LCC6 cells also retain the anchorage-dependent and anchorage-independent in vitro
growth properties of the parental MDA-MB-435 cells, and can be used in standard in vitro drug screening
assays. The drug resistance pattern of the MDA435/LCC6 cells suggests that they may have few active
endogenous drug resistance mechanisms. To generate a model for the screening of MDRl-reversing agents,
MDA435/LCC6 were transduced with a retroviral vector directing the constitutive expression of the MDR1
cDNA, producing a cell line with a classical MDR1 resistance pattern (MDA435/LCC6MDRI). These ascites
models may be a viable alternative to the murine leukaemia ascites (L1210, P388) and, in conjunction with
other breast cancer cell lines, facilitate the in vitro and in vivo screening of new cytotoxic drugs and drug
combinations.
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Approximately 11% of all women in western Europe and the
USA living to age 80 will develop breast cancer. An annual
worldwide incidence of one million is predicted by the year
2000 (Miller and Bulbrook, 1986). Despite several decades of
research, the majority of patients with metastatic breast
disease will ultimately fail systemic cytotoxic and endocrine
therapies. Clearly, there is a need to identify new and
effective treatments for metastatic breast cancer.
The lack of suitable in vitro/in vivo human breast cancer
models for drug screening has been a major restriction in the
identification of new agents. In previous years, several drug
screening programmes have used the P388 and L1210 murine
ascites models as a major part of their in vivo programme.
The ease of in vitro and in vivo maintenance, and the ability
to perform reproducible and rapid estimations of the
incidence of long-term survivors and percentage increased
lifespan (%ILS), are considered significant advantages. While
still frequently used for preclinical drug evaluation, the
limitations of the P388 and L1210 models are now widely
acknowledged. This reflects their non-human derivation and
relatively poor performance in identifying agents active
against the more common solid tumours, e.g. breast, lung,
colon (Boyd, 1989).
The current screening at the National Cancer Institute
(USA) uses an initial in vitro screen against a panel of human
and animal cancer cell lines (Boyd 1989). Subsequent in vivo
screens are performed against these cells growing in rodents.
However, new models are needed and these must be
amenable to both in vitro and in vivo analyses. The inclusion
of additional human breast cancer models with appropriate
in vivo and in vitro growth characteristics is critical to the
development of a representative panel of models with which
to screen agents for anti-tumour activity against breast
cancer.
To address several of the concerns associated with using a
non-human in vivo screen, e.g. P388, L1210, we have isolated
and characterised an ascites model of human breast cancer
(MDA435/LCC6). The MDA435/LCC6 ascites were derived
from the oestrogen receptor (ER)-negative, invasive and
metastatic MDA-MB-435 cell line (Cailleau et al., 1974; Price
et al., 1990). Mice bearing these ascites tumours have a
reproducible life span, a pattern of responsiveness to
cytotoxic drugs similar to many human breast cancer
patients, form rapidly proliferating solid tumours, and are
readily adapted for growth in vitro. These cells provide a
novel model for the in vitro and in vivo screening of experi-
mental agents for antineoplastic activity against breast
cancer.
While many breast tumours are often initially responsive
to cytotoxic chemotherapy, the development of a drug-
resistant phenotype in metastatic breast cancer is ultimately
responsible for the failure of current cytotoxic regimens
(Clarke et al., 1992a). Acquired resistance may be associated
with expression of the MDR] gene and its gpl70 glyco-
protein product (Goldstein et al., 1989). The level and/or
incidence of detectable MDRI/gpl70 expression is
significantly higher in the tumours of treated vs untreated
breast cancer patients (Schneider et al., 1989; Sanfilippo et
al., 1991; Koh et al., 1992) and correlates with in vitro
resistance to cytotoxic drugs (Salmon et al., 1989; Sanfilippo
et al., 1991; Veneroni et al., 1994). The precise role of gpl70
in the clinical resistance of breast and other solid tumours
remains to be established. However, it seems likely that
where it is clearly expressed it contributes, in some part, to
the resistance phenotype. We also wished to establish an
appropriate model for screening potential drug resistance
modulating agents. We have previously described an ER-
positive model of MDR1 resistance, derived by the introduc-
tion of the MDR1 cDNA into the hormone-dependent
MCF-7 human breast cancer cell line (Clarke et al., 1992b).
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To generate a comparable ER-negative model, we have also
introduced the MDR1 cDNA into the MDA435/LCC6
ascites cells.
Materials and methods
Cell culture
The parental MDA-MB-435 cells were originally provided by
Dr Janet Price (MD Anderson Cancer Center, Houston, TX,
USA), and were established from a pleural effusion in a
31-year-old Caucasian woman with metastatic breast cancer
(Cailleau et al., 1974, 1978). The patient had received no
prior systemic therapy (J. Price, personal communication).
MDA-MB-435 is one of the few human breast cancer cell
lines that produces reproducible lung metastases from solid
tumours (Price et al., 1990; Meschter et al., 1992). The
MCF-7ADR clone 5 cells are a cloned population of MCF-
7ADR, and were kindly provided by M. Johnson (Lombardi
Cancer Center). MDA-MB-435,MCF-7ADR clone 5, MDA-
435/LCC6 and MDA435/LCC6MDRl cells were routinely
maintained in improved minimal essential medium (IMEM;
Biofluids, Rockville, MD, USA) containing phenol red and
supplemented with 5% fetal calf serum.
Isolation ofMDA435/LCC6 cells
For the isolation of MDA435/LCC6 cells, MDA-MB-435
cells growing in vitro were removed, centrifuged and the cell
pellet resuspended in growth medium. An aliquot was
counted, cell viability estimated by trypan blue dye exclusion
and 2 x 106 cells inoculated into the mammary fat pads of 4
to 6 week-old, specific pathogen-free, female, NCr nu/nu
athymic mice. Cells from a subsequent spontaneous ascites
were removed, maintained as an ascites by transplantation
i.p. into other NCr nu/nu athymic mice and concurrently
established in vitro as a monolayer culture. Both serial ascites
and cell cultures of the MDA435/LCC6 cells have been
routinely maintained for over 2 years. All studies using
vertebrate animals were performed in accordance with insti-
tutional and NIH guidelines. As required, preapproval for
these studies was obtained from the Georgetown University
Animal Care and Use Committee.
Isozyme and karyotype analyses
To exclude the possibilities of contamination with either
mouse stromal tissue or other breast cancer cell lines, the
MDA-MB-435 origin of the ascites was investigated by both
isozyme pattern and karyotype analyses. These studies were
performed by W Peterson and J Kaplan (Children's Hospital
of Michigan, Detroit, MI, USA). The polymorphic enzymes
analysed were lactate dehydrogenase, glucose-6-phosphate
dehydrogenase (EC 1.1.1.49), phosphoglucomutase-I (EC
2.7.5.1), phosphoglucomutase-3 (EC 2.7.5.1), esterase D (EC
3.1.1.1), mitochondrial malic enzyme (EC 1.1.1.40), adenylate
kinase (EC 2.7.4.3) and glyoxalase (EC 4.4.1.5).
Estimation ofsolid tumour doubling time
To determine the ability of cells to produce solid tumours
and to estimate tumour doubling times, MDA435/LCC6 cells
(1 x 106) were obtained from an ascites and inoculated s.c.
into the mammary fat pads of NCr nu/nu athymic nude mice.
Tumour area was recorded every 2-3 days by measuring the
length of the longest axis and the width perpendicular to the
longest axis. The 'GROWTH' tumour growth curve analysis
software was used to apply Gompertzian kinetics to the
tumour growth data (Rygaard and Spang-Thomsen, 1989). A
similar analysis was performed using NCr rnu/rnu athymic
nude rats.
Ascites propagation and estimation ofin vivo anti-tumour
activity
The ascites were propagated by collecting ascites fluid from a
previous ascites, pelleting the cells by centrifugation at 1000 g
for 10 min and inoculating 1 x 106 viable cells i.p. into nude
mice. Viability was assessed by trypan blue exclusion. For
estimations of anti-tumour activity, cells were inoculated on
day 0 and each cytotoxic drug administered i.p. as a single
dose within 24 h post inoculum. Anti-tumour activity was
determined by estimating the incidence of long-term (>90
days) survivors and %ILS as previously described (Dhainaut
et al., 1992).
Estimation ofin vitro anti-tumour activity
In vitro cytotoxicity was determined using a crystal violet dye
uptake assay as previously described (Leonessa et al., 1994).
At day 0 MDA435/LCC6 cells (1 x 103) were plated into
96-well culture dishes (Costar, Cambridge, MA, USA).
Forty-eight hours later (day 2) cells were exposed to drug
(IMEM containing 0.1% (v/v) ethanol), and after a further
24 h (day 3) cells were refed with fresh IMEM without drug.
All treatments were stopped at the end of day 3 (24 h treat-
ment), and the wells rinsed and refed with fresh growth
medium. Following incubation in the absence of drug for
72 h, cells were washed twice in phosphate buffer and stained
with crystal violet solution [0.5% (w/v) crystal violet in 25%
(v/v) methanol] for 5 min at 25°C. The stained cell
monolayers were rinsed gently with distilled water, allowed to
dry and the dye extracted into 0.1 M sodium citrate/50%
(v/v) ethanol by incubation at room temperature for 10-15
min. Absorbance was read at 540 nm using a Dynatech
MR700 ELISA reader (Dynatech, Chantilly, VA, USA). The
degree of dye uptake as measured by absorbance is directly
related to cell number (Leonessa et al., 1991; Frandsen et al.,
1992).
Transduction ofMDA435/LCC6 ascites cells with the MDR]
gene
An amphotropic retrovirus containing the coding sequence of
the full length MDR1 cDNA was used to transduce rapidly
proliferating MDA435/LCC6 cells in vitro as previously des-
cribed (Pastan et al., 1988). Cells were infected with virus by
the addition of PA-12 cell supernatant (Pastan et al., 1988) to
exponentially proliferating MDA435/LCC6 cells twice, with a
24 h gap between each addition. Transduced cells (1 x 106)
were then selected in the presence of either 100 ngml-' or
400 ngml-' colchicine for a period of at least 3 months. The
stability of the transduced cells was confirmed on removal of
the selective pressure. All experiments were performed in cells
that had been maintained in the absence of colchicine for at
least 3 months. Unless otherwise indicated, all analyses were
performed on cells selected against 100 ngml-' colchicine.
Western blotting
Expression of gpl7O was determined in both transduced and
parental MDA435/LCC6 cells by Western blotting with the
Ab-l polyclonal anti-gpl70 antibody (Oncogene Science,
Cambridge, MA, USA). MCF-7ADR clone 5 cells were
included as a positive control. Subconfluent cells (90% conf-
luence) were collected by trypsinisation and counted. The cell
pellet was rinsed three times with Dulbecco's phosphate-
buffered saline (PBS) and total cellular proteins extracted for
40 min on ice into buffer containing 1% Nonidet P-40,
150 mM sodium chloride, 50 mM Tris-HCl at pH 7.50. Fol-
lowing centrifugation for 5 min at 4°C in a benchtop mic-
rofuge, the pellets were discarded and the protein concentra-
tion in the supernatant evaluated using the Bradford Assay
(Bio-Rad Laboratories, Richmond, CA, USA). Proteins were
separated by molecular weight by electrophoresis in sodium
dodecyl sulphate/Tris/glycine/polyacrylamide (4-12% grad-
ient) gels and blotted onto nitrocellulose membranes. gp-170
was detected by exposing the nitrocellulose membranes to
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1lggml-h of the Ab-1 anti-gpl70 antibody (Oncogene
Science) for 3 h. The labelled band was detected using the
ECL Western blotting detection kit as described by the
manufacturer (Amersham, Arlington Heights, IL, USA).
Fluorescence-activated cell sorting analysis ofgpl70 expression
MDA435/LCC6 and MDA435/LCC6MDRl cells selected in
colchicine (100 ng ml' or 400 ng ml-') were analysed by
fluorescence-activated cell sorting (FACS) for expression of
gpl70. Cells were trypsinised and washed in PBS containing
0.1% bovine serum albumin (BSA) (PBS-B). Approximately
2.5 x 105 cells were stained for 20 min at 4°C with either the
anti-gpl70 antibodies MRK16 (a gift from Hoechst Japan)
or UIC2 (kindly provided by I Roninson), or an isotype-
identical non-specific antibody (Pharmingen, San Diego, CA,
USA). Cells were washed with PBS-B followed by staining
with a 1:20 dilution of a FITC-labelled goat-anti-mouse IgG
antiserum (Jackson, West Grove, PA, USA) for 20 min at
4°C. Cells were washed twice with PBS-B, and analysed with
a FACSort cytometer using the LYSIS II software (Becton-
Dickinson, San Jose, CA, USA).
[3H]VBL accumulation
The effect of gpl7O expression on [3H]VBL accumulation was
determined as previously described (Leonessa et al., 1994).
Cells (105) were seeded into 24-well dishes (Costar) and
incubated with 50 nM [3H]VBL (final sp. act. 2.24 Cimmol-';
Amersham) for increasing periods from 60 s to 3 h at 37°C.
Following incubation, cells were rinsed three times with 250jd
of buffer (IMEM: 0.1% BSA; 50mM Hepes; pH 7.4). Cells
were trypsinised and total cell-associated radioactivity deter-
mined by liquid scintillation spectrometry. Curves were fitted
to the data points by applying the equation y = Bta,(TI
T+ Kin) using the curve-fitting algorithms in SigmaPlot for
Windows vs 2.0 (Jandel Scientific, San Rafael, CA, USA).
B,,., = maximum intracellular ligand, T = time, Kin = time
required to achieve 50% total intracellular drug accumula-
tion (Leonessa et al., 1994).
Results
Origin andpathogenesis ofMDA435/LCC6 cells
The MDA435/LCC6 cells were isolated from a spontaneous
ascites that developed in a NCr nu/nu athymic nude mouse
bearing a MDA-MB-435 tumour in the mammary fat pad.
Cells were re-established as a monolayer culture in vitro and
designated MDA435/LCC6. Karyotype analyses (Table I)
indicate that the cells are human, derived from a woman, and
are a unique subline of MDA-MB-435 cells, there being 14
marker human chromosomes in common, two unique to
MDA435/LCC6 cells and four unique to the parental MDA-
MB-435 cells. Mouse chromosomes are absent. Table II
reports the isozyme profiles of the parental (MDA-MB-435)
and variant (MDA435/LCC6) cells, with that of the MDA-
MB-231 and MCF-7 cell lines provided for comparison. The
probability that another cell line would express this isoen-
zyme profile (Table II) is estimated to be P = 0.0066. The
patterns are consistent with those reported by Siciliano et al.,
(1979). The serially passaged ascites were assayed for their
isozyme patterns twice, in June 1991 and again in October
1994. The ascites had remained without contamination by
mouse or other human cells throughout this time. Together,
the isozyme and karyotype analyses confirm that the
Table I Karyotypes of parental MDA-MB-435 and variant MDA435/LCC6 cells
Marker
Chromosome Chromosome origins MDA-MB-435 MDA435/LCC6
I t(lq;7q) +
1A t(lp;?) +
lB del(7) (ql2q31) +
2 del(3) (p21:) + +
2A del(3) (p2lp24) + +
3 del(6) (ql2q21) + +
4 8q+ +
4A del(8) (pl lp21) +
5 t(llq;13q) + +
5A t(IIq;14q) + +
6 14p+(HSR) + +
7 20q+ + +
8 22p+ + +
9 del(18) (ql2q22) + +
10 22p+ =t?(llp;22q) + +
11 Unknown acrocentric + +
12 Unknown metacentric + +
13 t=(9p;?) + +
13A del(9) (qI 1:) +
14 Small unknown metacentric + +
Chromosome I Monosomic Disomic
Chromosome 8 Monosomic Disomic
Chromosome 5 Trisomic Disomic
Chromosome 7 Disomic Monosomic
Eight karyotypes were examined. Del, deletion; HSR, homogeneously staining
region; t, translocation; ?, precise origin or location unclear.
Table II Isoenzyme profile of parental MDA-MB-435 and variant MDA435/LCC6 cells
Cell Line LDH GLOI G6PD PGM1 PGM3 ESD AK] Me-2
MDA-MB-435 Human 5 2 B 2 1 1 ND ND
MDA435/LCC6 Human 5 2 B 2 1 1 1 Absent
MDA-MB-231 Human 5 2 B 1,2 1 1 1 ND
MCF-7 Human 5 1,2 B 1 1 1 1 Absent
LDH, lactate dehydrogenase; GLO-1, glyoxalase; G6PD, glucose-6-phosphate dehydrogenase; PGM1,
phosphoglucomutase-l; PGM3, phosphoglucomutase-3; ESD, esterase D; AK1, adenylate kinase; Me-2,
mitochondrial malic enzyme; ND, no data.
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MDA435/LCC6 cells represent a novel variant of the MDA-
MB-435 cell line.
The ascites are generally accompanied by the presence of
one or more solid deposits in the peritoneal cavity. These
tumours are characterised by pleomorphic epithelial cells
arranged in a nesting pattern. The cells exhibit oval vesicular
and occasionally folded nuclei, 1-2 prominent nucleoli and a
scant to moderate eosinophilic cytoplasm. These tumours are
generally palpable before the detection of visible ascites and
closely resemble tumours arising from the parental MDA-
MB-435 cells. It seems most likely that these deposits give
rise to the ascites by continually shedding of cells into the
peritoneal cavity.
Growth ofthe MDA435/LCC6 cells in vivo and in vitro
MDA435/LCC6 cells grow both as ascites and as solid
tumours. The duration of survival of untreated mice bearing
MDA435/LCC6 ascites is highly reproducible (Table III),
with death occurring between days 29-33 post inoculum. In
most studies all untreated animals with ascites usually die
within 24-48 h of each other. The onset of morbidity also is
highly reproducible, and assessment of morbidity rather than
death may provide a reliable but more humane end point for
many studies.
The tumours grow in the mammary fat pad with an
incidence of 100%. The tumour doubling time for MDA435/
LCC6 tumours in nude mice is approximately 2.3 ± 0.7 days,
compared with 12 days for ER-positive MCF-7 tumours in
oestrogen-supplemented mice (Clarke et al., 1989). We also
have successfully established MDA435/LCC6 solid tumours
in NCr rnu/rnu athymic nude rats. The cells exhibit similar
tumour growth kinetics in nude rats (2.44 ± 0.6 days) when
compared with their growth in nude mice.
Sensitivity ofMDA435/LCC6 ascites to cytotoxic drugs
The MDA435/LCC6 ascites is sensitive to a range of drugs
with known activity against human breast cancer (Table IV),
Table III Mean survival time of untreated NCrnu/nu athymic mice
bearing MDA435/LCC6 ascites in five separate studies.
Experiment n Survival (days)
1 5 31.6±0.7
2 5 32.7±0.8
3 5 29.0±1.7
4 4 32.0±1.1
5 4 29.8±1.0
Approximately 106 cells were injected i.p. on day 0; n, number of
mice. Data represent mean and standard deviation.
and the pattern of long-term survivors appears to closely
reflect the pattern of clinical responses observed in previously
untreated breast cancer patients. For example, long-term sur-
vivors were readily detected following treatment with doxo-
rubicin (DOX) (Henderson and Shapiro, 1991), taxol (TAX)
(Donehower and Rowinsky, 1994) and mitomycin C (MITC)
(Garewal, 1988), drugs which have proven efficacy as single
agents in previously untreated human breast cancer patients.
We also estimated percentage increased life span (%ILS) for
several drugs. TAX, which produced no deaths due to tox-
icity, produced two out of five long-term survivors and an
estimated %ILS of> 122%. A combination of WR2721 and
DOX produced a %ILS of> 145% (Green et al., 1992).
Cisplatin produced two out of three long-term survivors and
a 138% %ILS. In contrast, we did not detect significant
activity with BCNU, a drug with little activity in human
breast cancer (Henderson and Shapiro, 1991). WR2721 is a
potential chemoprotective agent with no reported anti-
tumour activity (Treskes et al., 1991). As expected, this drug
also produced no activity in the MDA435/LCC6 ascites
model.
We have also determined the ability of i.v. drug administ-
ration to increase survival of mice inoculated with the
MDA435/LCC6 ascites. Preliminary data indicate that
15 mg kg' TAX administered i.v. on days 11, 15 and 19
produces a %ILS of 126%. There were no long-term sur-
vivors (0/5) and no deaths due to drug toxicity (0/5).
Characterisation ofMDA435/LCC6 ascites cells transduced
with the MDR] gene (MDA435/LCC6MDR`)
We performed a Western blot analysis of total cellular pro-
teins to demonstrate that transduction produced elevated
levels of gpl7O. The data in Figure la clearly demonstrate
that the expression of gpl7O in the MDA435/LCC6 cells in
vitro is below the limit of detection. In contrast, the trans-
duced cells (MDA435/LCC6MDRi) express levels of gpl7O
similar to the MCF-7ADR clone 5 cells. This pattern of expres-
sion is equivalent when the cells are grown as solid tumours
(Figure lb). There is also no detectable endogenous gpl7O
expression in the MDA435/LCC6 cells by FACS analysis
(Figure 2a). The MDA435/LCC6MDR' cells, whether selected
in 100 ngml' (Figure 2b) or 400 ng ml' (Figure 2c) col-
chicine, express high levels of gpl7O by FACS analysis.
To assess the functionality of the expressed gpl70, we
compared the kinetics of [3H]VBL accumulation in the trans-
duced and non-transduced cells. The steady-state intracellular
VBL levels are clearly significantly lower in the MDA435/
LCC6MDR1 cells when compared with the MDA435/LCC6
cells (Figure 3). This is consistent with increased efflux of
[3H]VBL conferred by the action of gpl70, and confirms the
functionality of the expressed MDR1 product.
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Table IV Response of MDA435/LCC6 ascites to a single dose of cytotoxic drugs
Drug Dose n Toxicity/ 90 dayS" Clinical datad
Saline NA 15 0 0 NA
Doxorubicin 8.5 mg kg-' 6 3/6 2/3 43% (Henderson
Doxorubicin 6.8 mg kg-' 5 0/5 2/5 and Shapiro, 1991)
BCNU 18.0mg kg-' 5 1/5 0 16% (Henderson
and Shapiro, 1991)
Cisplatin 7.5mg kg-' 3 0/3 2/3 0-54%
(Henderson, 1991)
Etoposide 60.0mg kg-' 5 2/6 0 0-15%
(Henderson, 1991)
Mitomycin C 4.5mg kg-' 13 0/13 6/13 38% (Garewal,
1988)
Taxol 20.0mg kg-' 5 0/5 2/5 17-56%
(Donehower and
Rowinsky, 1994)
WR-2721 300mg kg-' 7 0/7 0 ND
Approximately I x 106 cells were injected i.p. on day 0. Each drug was administered as a single dose on
day 1. aDrug-induced deaths. bMice which survive to 90 days or longer (drug toxicity-related deaths are
excluded). cResponse rates when drug is administered as a single agent in breast cancer; numbers in
parentheses are literature citations. NA, not applicable; ND, no data.
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The MDA435/LCC6MDRl cells grow in vivo as both an
ascites and as solid tumours (not shown). The growth charac-
teristics of these tumours is similar to that observed in the
parental MDA435/LCC6 cells, with the mean survival in
untreated mice being 34 ± 3 days (n = 10). These cells appear
resistant to DOX in vivo, for which the mean survival was
37 ± 5 days (n = 7; 3 deaths due to toxicity excluded) follow-
ing treatment with an appropriate DOX regimen
(4.0mgkg-' i.p. on days 0, 4, 8, 12).
In vitro responses ofMDA435/LCC6MDRJ to DOX, TAX and
VBL
We wished to assess the effects of the high level of gpl70
expression on the dose response to known gpl70 substrates.
Consequently, we have determined the respective response of
the MDA435/LCC6 and MDA435/LCC6MDRl cells in vitro to
DOX, TAX and VBL. The data in Figure 4 clearly indicate
that the IC50 for all three drugs is significantly increased in
the MDR1-transduced drug-resistant cells relative to the non-
transduced cells. These data also further substantiate the
functionality of the expressed gpl7O, and confirm the utility
of the MDA435/LCC6MDRl cells as a model for the screening
of MDR1-reversing agents.
Discussion
A significant proportion of breast cancer patients (25-50%)
develop malignant effusions in the pleural or peritoneal
cavities (Fracchia et al., 1970; De Vita, 1989). In addition to
paracentesis for the removal of fluid, some ascites are
amenable to intraperitoneal chemotherapy (Fracchia et al.,
1970; Goldman et al., 1993). A significant proportion of all
breast tumours (35-40%) are ER negative, and the incidence
of ER-negative tumours increased 22-27% over the period
1974-1985 (Glass and Hoover, 1990). When compared with
ER-positive tumours, ER-negative tumours are frequently
more poorly differentiated (Singh et al., 1988), proliferate
more rapidly (Meyers et al., 1977; Jonat and Maat, 1978)
and the patients have a poorer prognosis (Shek and God-
lophin, 1989). We now describe the isolation of the first
ascites model of human breast cancer (MDA435/LCC6). We
have derived these cells from the ER-negative MDA-MB-435
cell line.
The choice of the MDA-MB-435 cells reflects the relative
novelty of several aspects of this cell line. For example, the
MDA-MB-435 cells were derived from a pleural effusion in a
premenopausal woman (Cailleau et al., 1974, 1978) who had
received no prior systemic therapy (J Price, personal com-
munication). Thus, the MDA-MB-435 cells may have few
active endogenous resistance mechanisms and may exhibit a
pattern of drug responsiveness similar to the majority of
untreated breast cancer patients. This appears to be substan-
tiated by the pattern of response of these cells both in vitro
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and in vivo to various cytotoxic drugs with diverse
mechanisms of action. The MDA-MB-435 cells also are
capable of producing distant metastases and occasional
ascites from solid mammary fat pad xenografts (Price et al.,
1990) and we wished to establish a stable ascites variant.
We studied the response of the MDA435/LCC6 ascites to
representative agents with known activity in breast cancer
patients. To assess the activity of likely endogenous resis-
tance mechanisms, we chose a series of drugs with different
mechanisms of action. Thus, we used the anthracycline DOX,
which can both generate free radicals and inhibit topo-
isomerase II (Myers and Chabner, 1990), the nitrosourea
BCNU, which can alkylate DNA (Colvin and Chabner,
1990), the taxane TAX, which stabilises microtubules (Bender
et al., 1990), the epipodophyllotoxin VP-16, which inhibits
topoisomerase II (Bender et al., 1990), cisplatin, which forms
DNA adducts (Reed and Kohn, 1990), and the antibiotic
MITC which can cross-link DNA and generate free radicals
(Ghiorghis et al., 1991). For comparison, two non-cytotoxic
treatments were included, saline (the vehicle for most of the
drugs) and WR-2721 (Treskes et al., 1991; Green et al.,
1992). Most drugs were administered at or near their
anticipated maximum tolerated dose and/or LD10 (Berger et
al., 1991), producing approximately equitoxic treatments.
Since BCNU and VP-16 might be expected to have less
activity than the other agents against breast cancer cells
(Henderson, 1991), these drugs were administered at higher
doses. This is evidenced by the increased toxicity of these
drugs relative to the others (Table IV).
The pattern of response to this selection of agents appears
to reflect closely that seen in breast cancer patients. For
example, breast cancers in general respond poorly to nit-
rosoureas (Goldman et al., 1993), and this is mirrored by the
poor response of MDA435/LCC6 cells to BCNU. VP-16 also
did not produce long-term survivors, and this drug generally
has been ineffective as a single agent in breast cancer
(Henderson and Shapiro, 1991; Henderson, 1991). In con-
trast, DOX (Henderson and Shapiro, 1991), MITC (Garewal,
1988) and TAX (Donehower and Rowinsky, 1994) are
among the most effective single agents in previously un-
treated breast cancer, and all of these drugs produced long-
term survivors. Cisplatin is generally associated with the
management of ovarian cancer, a disease in which malignant
ascites also occur with a high frequency. However, it also
produced long-term survivors in mice bearing the MDA435/
LCC6 ascites. While not widely used in breast cancer, several
studies have indicated that it may be useful as a first-line
treatment, with response rates as high as 52% reported
(Henderson and Shapiro, 1991). While the response rate in
pretreated breast cancer patients can be lower (Henderson
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Figure 4 In vitro response of MDA435/LCC6 and MDA435/
LCC6MDRI cells to cytotoxic drugs. 0, MDA435/LCC6 cells; @,
MDA435/LCC6MDRI cells. The data are presented as the mean of
the optical density (OD) expressed as a percentage of untreated
cell populations, and represent the mean ± s.d. of six or more
determinations.
and Shapiro, 1991), the response in the MDA435/LCC6
ascites is consistent with the origin of the parental cells from
an untreated patient.
The MDA-MB-435 cells are among the few breast cancer
cell lines that reproducibly metastasise in nude mice (Price et
al., 1990; Meschter et al., 1992). We have not studied the
metastatic potential of the ascites variant, since the life span
of mice bearing the ascites tumour is probably too short to
allow metastases to arise. The parental cells require 8-12
weeks to produce a high incidence of lung metastases (Price
et al., 1990). We would expect the MDA435/LCC6 cells
growing as solid tumours to exhibit a similar metastatic
potential as the parental cells. Studies to determine the ability
of both MDA435/LCC6 and MDA435/LCC6MDRl tumours
to metastasise are currently in progress.
The multidrug-resistant phenotype is often accompanied
by the expression of the MDR] gene and/or its gpl70 glyco-
protein product, both of which are widely detected in treated
human breast tumours. Detectable gpl70 expression in breast
tumours increases with induction chemotherapy. (Koh et al.,
1992), and correlates with failure of cytotoxic chemotherapy
(Goldstein et al., 1989; Sanfilippo et al., 1991), poor prog-
nosis (Verrelle et al., 1991), poor survival (Verrelle et al.,
1991; Botti et al., 1993) and/or in vitro resistance of human
breast cancer biopsies to cytotoxic drugs (Salmon et al.,
1989; Sanfilippo et al., 1991). The precise role of MDR1/
gpl70 in breast cancer remains to be definitively established,
but it seems highly likely that in tumours in which expression
is detectable this expression contributes to the multidrug-
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resistant phenotype. This does not exclude the possibility that
gpl70 expression is superimposed upon the expression of
other resistance mechanisms. For example, MCF-7 cells
selected in vitro for resistance to DOX (MCF-7"R) overex-
press gpl70 (Vickers et al., 1988) and also exhibit altered
manganous superoxide dismutase (Zyad et al., 1994),
glutathione transferase and topoisomerase II activities (Batist
et al., 1986; Sinha et al., 1989). These cells also have lost ER
and PgR expression and have acquired anti-oestrogen resis-
tance (Vickers et al., 1988). Where gpl70 contributes to the
multiple drug resistance phenotype, this contribution must be
eliminated if chemotherapy is to be curative. Consequently,
there is a need to provide models in which gpl70 is the only,
or at least the primary, resistance mechanism.
The MCF-7ADR cells have been widely used in gpl7O-
reversing studies, but effects on cytotoxicity cannot readily be
attributed solely to effects on gpl70 in these cells. The
tamoxifen cross-resistance in MCF-7ADR is the result of the
loss of ER and not gpl70 expression (Clarke et al., 1992b),
despite the ability of tamoxifen to reverse gpl70 function,
implying that tamoxifen may be a classical gpl70 substrate
(Ramu et al., 1984; Leonessa et al., 1994). Furthermore,
differences in the potency of flupenthixol isomers observed in
MCF-7ADR cells could not be confirmed in NIH 3T3 cells
transfected with the MDR1 cDNA, implying a non-gpl7O-
mediated effect on drug resistance (Ford et al., 1990). While
concurrently expressed drug resistance mechanisms may
ultimately prove to be more clinically relevant, cells with
multiple resistance mechanisms are not optimal for assessing
drugs/combinations specifically selected or designed to
reverse gpl7O-mediated resistance. To directly address this
concern, we have previously generated an ER-positive model
(CL 10.3) for screening endocrine-based modalities by trans-
ducing MCF-7 cells with the MDR1 cDNA (Clarke et al.,
1992b). We have already used the ER-positive model, in
conjunction with the MCF-7ADR cells, to exclude ER-
mediated events in the reversal of gpl70 resistance by the
anti-oestrogen tamoxifen (Leonessa et al., 1994).
To generate an appropriate ER-negative gpl7O-resistant
model for future studies, we have now transduced MDA435/
LCC6 cells with a vector similar to that used to generate the
CL 10.3 cells. We isolated a population of cells (MDA435/
LCC6MDRI) that express a classical MDR1 phenotype.
MDA435/LCC6MDR', but not MDA435/LCC6 cells, express
high levels of the gpl70 product as determined by Western
blotting with an anti-gpI70 polyclonal antibody. Thus, the
inserted cDNA is clearly transcribed and the resultant
mRNA translated. Function of the expressed gpl7O is
evidenced by the significant increase in the ICO for DOX,
VBL and TAX. The MDA435/LCC6MDRl cells also retain
their tumorigenicity in vivo, indicating that they also may be
useful as an in vivo model for screening gpl70 reversing
agents.
The MDA435/LCC6 and MDA435/LCC6MDRI cells pro-
vide a potentially novel alternative to the murine leukaemia
ascites (L1210, P388) and also provide a potential solid
tumour system. Thus, in conjunction with other breast cancer
cell lines, these cells facilitate the in vitro and in vivo screen-
ing of new cytotoxic drugs and drug combinations. For
example, the tumorigenicity of these cells is approximately
100% in untreated nude mice and rats. The ascites facilitate
both assessment of long-term survivors and %ILS as in vivo
end points, and studies into the dynamics and route of
tumour spread from ascites in nude mice. The solid tumours
are amenable to the estimation of anti-tumour activity on
established tumours e.g. tumour growth delay (Moulder and
Rockwell, 1987) and excision assays (Hill, 1987). When grow-
ing in vitro, MDA435/LCC6 and MDA435/LCC6MDRI cells
can be used in any of the various anchorage-dependent and
anchorage-independent growth inhibitory assays.
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